HK1219879A1 - 用於治療癌症的包含 激酶抑制劑和有絲分裂抑制劑的組合 - Google Patents

用於治療癌症的包含 激酶抑制劑和有絲分裂抑制劑的組合

Info

Publication number
HK1219879A1
HK1219879A1 HK16107918.6A HK16107918A HK1219879A1 HK 1219879 A1 HK1219879 A1 HK 1219879A1 HK 16107918 A HK16107918 A HK 16107918A HK 1219879 A1 HK1219879 A1 HK 1219879A1
Authority
HK
Hong Kong
Prior art keywords
mps
inhibitor
cancer
combinations
treatment
Prior art date
Application number
HK16107918.6A
Other languages
English (en)
Inventor
Antje Margret Wengner
Gerhard Siemeister
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48576906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1219879(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1219879A1 publication Critical patent/HK1219879A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16107918.6A 2013-06-11 2016-07-07 用於治療癌症的包含 激酶抑制劑和有絲分裂抑制劑的組合 HK1219879A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171517 2013-06-11
PCT/EP2014/061772 WO2014198645A1 (en) 2013-06-11 2014-06-06 Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor

Publications (1)

Publication Number Publication Date
HK1219879A1 true HK1219879A1 (zh) 2017-04-21

Family

ID=48576906

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107918.6A HK1219879A1 (zh) 2013-06-11 2016-07-07 用於治療癌症的包含 激酶抑制劑和有絲分裂抑制劑的組合

Country Status (16)

Country Link
US (1) US20160128988A1 (zh)
EP (1) EP3007692A1 (zh)
JP (1) JP2016520665A (zh)
KR (1) KR20160018534A (zh)
CN (1) CN105283178A (zh)
AU (1) AU2014280354A1 (zh)
CA (1) CA2914742A1 (zh)
CL (1) CL2015003585A1 (zh)
EA (1) EA201600003A1 (zh)
HK (1) HK1219879A1 (zh)
MA (1) MA38656A1 (zh)
MX (1) MX2015017120A (zh)
PH (1) PH12015502757A1 (zh)
SG (1) SG11201509350RA (zh)
TN (1) TN2015000543A1 (zh)
WO (1) WO2014198645A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3008062T3 (pl) * 2013-06-11 2017-08-31 Bayer Pharma Aktiengesellschaft Pochodne proleki podstawionych triazolopirydyn
MX2018012508A (es) * 2016-04-15 2019-07-08 Felicitex Therapeutics Inc Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis.
LT3474841T (lt) 2016-06-22 2022-06-10 Ellipses Pharma Ltd Ar+ krūties vėžio gydymo būdai
CN106117202B (zh) * 2016-06-29 2018-06-26 四川大学华西医院 具有抗肿瘤活性的[1,2,4]三唑并[1,5-a]吡啶衍生物晶型
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5721268A (en) 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
HU229833B1 (en) 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CA2281105A1 (en) 1997-02-25 1998-09-03 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilones with a modified side chain
US5902822A (en) 1997-02-28 1999-05-11 Bristol-Myers Squibb Company 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels
US6117659A (en) 1997-04-30 2000-09-12 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001510189A (ja) 1997-07-16 2001-07-31 シエーリング アクチエンゲゼルシヤフト チアゾール誘導体、その製造法および使用
DE59814067D1 (de) 1997-08-09 2007-09-06 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
HUP0100582A3 (en) 1997-12-04 2003-03-28 Bristol Myers Squibb Co A process for the reduction of oxiranyl epothilones to olefinic epothilones
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
RS54044B1 (en) * 2011-04-21 2015-10-30 Bayer Intellectual Property Gmbh TRIAZOLOPIRIDINI
WO2012160029A1 (en) * 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
EA027544B1 (ru) 2012-07-10 2017-08-31 Байер Фарма Акциенгезельшафт Способ получения замещенных триазолопиридинов
WO2014020043A1 (en) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer

Also Published As

Publication number Publication date
CN105283178A (zh) 2016-01-27
MX2015017120A (es) 2016-10-05
MA38656A1 (fr) 2018-05-31
CA2914742A1 (en) 2014-12-18
JP2016520665A (ja) 2016-07-14
SG11201509350RA (en) 2015-12-30
US20160128988A1 (en) 2016-05-12
KR20160018534A (ko) 2016-02-17
PH12015502757A1 (en) 2016-03-21
AU2014280354A1 (en) 2015-12-03
EP3007692A1 (en) 2016-04-20
EA201600003A1 (ru) 2016-06-30
TN2015000543A1 (en) 2017-04-06
WO2014198645A1 (en) 2014-12-18
CL2015003585A1 (es) 2016-07-08

Similar Documents

Publication Publication Date Title
HK1223089A1 (zh) 激酶抑制劑及其用途
EP3019491A4 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
IL243976B (en) kdm1a inhibitors for disease treatment
HK1251494A1 (zh) 治療癌症的方法和組合物
HK1220459A1 (zh) 激酶抑制劑
HRP20190888T8 (hr) Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
HK1221144A1 (zh) 用於治療癌症的包含 激酶抑制劑和胞苷類似物的組合療法
IL244353A0 (en) Compounds and use for cancer treatment
HK1219104A1 (zh) 激酶抑制劑
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
EP2968204A4 (en) TREATMENT WITH A PHOSPHODIESTERASE HEMMER
EP2986317A4 (en) INHIBITION OF RIP KINASES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
HK1219879A1 (zh) 用於治療癌症的包含 激酶抑制劑和有絲分裂抑制劑的組合
EP3733184C0 (en) PYRROLOPYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
HK1223547A1 (zh) 癌症治療方法
HK1205500A1 (zh) 用於癌症治療的激酶抑制劑
PL3082858T3 (pl) Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu
HK1222341A1 (zh) 咪唑並噠嗪衍生物與有絲分裂試劑的聯用藥用於治療癌症
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201323021D0 (en) Use of kinase inhibitors
GB201321227D0 (en) Use of kinase inhibitors
GB201309603D0 (en) Novel compounds and their use as kinase inhibitors
GB201305741D0 (en) Novel compounds and their use as kinase inhibitors
GB201307155D0 (en) Kinase inhibitors